AST-07X / Aston Sci. - LARVOL DELTA

The anti-tumor efficacy of Th1-specific TROP2 vaccine (AST-07X) in a triple-negative breast cancer murine model (AACR 2024) - P3 | "Sacituzumab govitecan, a Trop-2-directed antibody drug conjugate (ADC), has shown significant benefits associated with progression-free and overall survival compared to standard chemotherapy for treating metastatic TNBC; however, its toxic effects were more frequent than that of chemotherapy (NCT02574455). AST-07X that induce TROP2-specific Th1 anticancer immune responses, showed sufficient anti-tumor efficacy; these effects were evident under immunodeficient conditions, such as those of TNBC tumor-bearing athymic mice. Synergy effects were also induced via combined ADC administration. We are currently conducting further research on humanized mice to address the limitations of the immunodeficient murine model."

Preclinical • Breast Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • IFNG • TACSTD2

Aston Science attends the American Association for Cancer Research… Announcement of results from a total of 6 studies, including cancer treatment vaccine [Google translation] (MedigateNews) - "Aston Science announced on the 11th that it will present research results on a total of five cancer treatment vaccines and one cancer targeted treatment at the American Association for Cancer Research (AACR 2024) annual conference held in San Diego, USA from April 5th to 10th...The most notable announcement is the results of a phase 1 study of AST-021p, a cancer treatment vaccine being developed for advanced solid cancer. The safety and immunogenicity of AST-021p were confirmed through the first phase 1 administration to humans, and based on this, phase 2 clinical trials are currently being prepared...AST-07X, which targets the TROP2 antigen of cancer cells, induces a Th1 anti-cancer immune response and showed superior anti-tumor efficacy compared to TROP2 ADC in a mouse model with triple-negative breast cancer (TNBC) tumors....the results confirmed that a stronger synergy effect occurred when administered in combination with TROP2 ADC..."

P1 data • Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Th1-specific TROP2 vaccine (AST-07X) elicits strong antigen-specific T cell responses in vitro (SITC 2023) - "Conclusions TROP2 epitopes that were identified in the Th-Vac® discovery platform has been developed as a promising ‘off-the-shelf’ type Th1-specific therapeutic cancer vaccine (AST-07X). Additionally, the Th-Vac® platform were fully validated in terms of performance and its application would be expanded beyond a cancer vaccine."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Solid Tumor • CD4 • TACSTD2